The clinical trial for sodium phenylbutyrate in pediatric patients with spinal muscular atrophy (SMA) types II and III was aimed at establishing the maximum tolerated dose and assessing its effects on SMN levels. The trial was terminated due to poor compliance, indicating potential challenges in patient adherence to treatment protocols. This raises concerns regarding the commercial viability of sodium phenylbutyrate as a therapeutic option in this demographic. The SMA market is competitive, with existing therapies such as nusinersen (Spinraza) and onasemnogene abeparvovec (Zolgensma) already approved, which may limit the market entry of sodium phenylbutyrate unless significant efficacy is demonstrated. Further diligence is required to assess the potential for future studies or alternative formulations that could enhance compliance and therapeutic outcomes.